Castro, Fabíola Attié de 
; Mehdipour, Parinaz; Chakravarthy, Ankur; Ettayebi, Ilias; Loo Yau, Helen; Medina, Tiago Silva; Marhon, Sajid A.; Almeida, Felipe Campos de ; Bianco, Thiago Mantello ; Arruda, Andrea G. F.; Devlin, Rebecca; Figueiredo‐Pontes, Lorena Lobo de; Chahud, Fernando ; Cacemiro, Maira da Costa ; Minden, Mark D.; Gupta, Vikas; Carvalho, Daniel D. de
Fonte: British Journal of Haematology. Unidades: FCFRP, FMRP
Assuntos: BIOMARCADORES, INTERFERONS, LEUCEMIA MIELOIDE AGUDA, FARMACOTERAPIA, PROGNÓSTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CASTRO, Fabíola Attié de et al. Ratio of stemness to interferon signalling as a biomarker and therapeutic target of myeloproliferative neoplasm progression to acute myeloid leukaemia. British Journal of Haematology, v. 204, n. 1, p. 206-220, 2023Tradução . . Disponível em: https://doi.org/10.1111/bjh.19107. Acesso em: 16 nov. 2025.APA
Castro, F. A. de, Mehdipour, P., Chakravarthy, A., Ettayebi, I., Loo Yau, H., Medina, T. S., et al. (2023). Ratio of stemness to interferon signalling as a biomarker and therapeutic target of myeloproliferative neoplasm progression to acute myeloid leukaemia. British Journal of Haematology, 204( 1), 206-220. doi:10.1111/bjh.19107NLM
Castro FA de, Mehdipour P, Chakravarthy A, Ettayebi I, Loo Yau H, Medina TS, Marhon SA, Almeida FC de, Bianco TM, Arruda AG F, Devlin R, Figueiredo‐Pontes LL de, Chahud F, Cacemiro M da C, Minden MD, Gupta V, Carvalho DD de. Ratio of stemness to interferon signalling as a biomarker and therapeutic target of myeloproliferative neoplasm progression to acute myeloid leukaemia [Internet]. British Journal of Haematology. 2023 ; 204( 1): 206-220.[citado 2025 nov. 16 ] Available from: https://doi.org/10.1111/bjh.19107Vancouver
Castro FA de, Mehdipour P, Chakravarthy A, Ettayebi I, Loo Yau H, Medina TS, Marhon SA, Almeida FC de, Bianco TM, Arruda AG F, Devlin R, Figueiredo‐Pontes LL de, Chahud F, Cacemiro M da C, Minden MD, Gupta V, Carvalho DD de. Ratio of stemness to interferon signalling as a biomarker and therapeutic target of myeloproliferative neoplasm progression to acute myeloid leukaemia [Internet]. British Journal of Haematology. 2023 ; 204( 1): 206-220.[citado 2025 nov. 16 ] Available from: https://doi.org/10.1111/bjh.19107
